back to the future: what you should know about prevention ...wadepage.org/files/2019conf/2019 wade...
TRANSCRIPT
4/27/19
1
Back to the Future: What You Should Know About Prevention
of CVD
CarolH.Wysham,MDEndocrinologist
RockwoodClinic/MulticareHealthSystemClinicalProfessorofMedicineUniversityofWashington
WADEConferenceApril27,2019
Disclosures to Participants • NoticeofRequirementsforSuccessfulCompletion:Forsuccessfulcompletion,participantsarerequiredtobein
attendanceinthefullactivityandcompletetheprogramevaluationattheconclusionoftheeducationalevent.• PresenterConflictsofInterest/FinancialRelationshipsDisclosuresConsultant/AdvisoryPanel:Abbott,AstraZeneca,BoehringerIngelheim,Janssen,NovoNordisk,SanofiSpeaker’sBureau:AstraZeneca,BoehringerIngelheim,Insulet,Janssen,NovoNordisk,Sanofi
• DisclosureofRelevantFinancialRelationshipsandMechanismtoIdentifyandResolveConflictsofInterest:NursePlannerfoundnoissuewithconflictofinterestorbias.Speakeragreestotheconstraintsofshowinganylogosorpreferencetoanyproductorcompany.Speakerstatesslideswillbefreeofanybias.
• Non-EndorsementofProducts:AccreditedstatusdoesnotimplyendorsementbyAADE,ANCC,ACPEorCDRof
anycommercialproductsdisplayedinconjunctionwiththiseducationalactivity.• Off-labelUse:Participantswillbenotifiedbyspeakerstoanyproductusedforapurposeotherthanthatforwhich
itwasapprovedbytheFoodandDrugAdministration.
Objectives
• DescribemanagementofCVDanddiabetestherapiespriortoCVDTrials
• ExplorethehistoryandprocessofCardioVascularOutcomeTrials(CVOT)
• CompareandcontrastpublishedCVOTtrials• Identifyupcomingtrials• ExploretheroleofCDEinCV/DMmanagement• DiscussimplicationsofCVOTandroleofchangesmadeto2019ADAStandardsofCareguidelines
4/27/19
2
Diabetes Increases the Risk if Cardiovascular Disease
• 2foldincreaseinCoronaryHeartDisease1• 5foldincreaseinfirstMI2
• Poorerprognosis–increasedriskforCHF,CVA,death2,3• 2foldincreaseinsecondMI2• 2foldincreaseinischemicstroke1,4• 2–4foldincreaseinCVdeath5,6• 2to5foldincreaseinriskofheartfailure7-9
SawarNetal.Lancet2010;375:2215,2.HaffnerSMetal.NEnglJMed.1998:399:229.3.Malmbergketal.Circulation2000;102:1014.4.GoldsteinLBetal.Stroke.2011;42:517;5.TancrediMetalNEnglJMed2015;373:1720.6.GreggEWetal.DiabetesCare.2012;35:1252,7NicholsGAetal.DiabetesCare.2004:27:1879.8.BellDSHDiabetesCare2003;26:2433.9.NicholsGAetal.DiabetesCare2001;24:1614.
The Burden of Stroke in Patients with Diabetes
• Theage-adjustedprevalenceofstrokeinpatientswithdiabetesis9%1
• Fatalandnon-fatalischemicstrokeis2to6foldmorelikelyinpatientswithdiabetes1,2
• Inthose>65yearsoldwithdiabetes,16%ofCVmortalityisduetostroke3,4
• Strokeisalife-changingeventforpatients,theirfamiliesandcaregivers1,5
• Nonfatalstrokeisviewedasworsethandeathby45%ofthoseatrisk
1.GoldsteinLBetal.Stroke;42:517.2.SarkarNetalLancet2010;375:2215;BenjaminEJetal.Circulation2017;135:e145.4.http://heart.org/HEARTORG/Conditions/More/Diabetes/WhyDiabetesMatters.5.SmsaGPetal.AmHeartJ.1998;136:703.
The Burden of Heart Failure in Patients with Diabetes
• Thereissignificantoverlapbetweenheartfailureanddiabetescomorbidities1
• 35to45%ofpatientswithCHF(bothHF-refandHF-pef)havediabetes1
• 25%ofpatientswithdiabetesovertheageof65haveCHF2• Inadultswithdiabetesandheartfailure,mortalityoutcomesareworse,withmediansurvivalof4years2
1.PackerM.DiabetesCare2018;41:11.2.KannelWB,McGeeDL.JAMA1979;241:2035
4/27/19
3
ShahAD,LangenbergC,RapsomanikiE,etal.LancetDiabetesEndocrinol.2015;3(2):105-13.
N=1,921,260 in England; ≥30 years and free of CVD at entry
Within 5 years of availability of
insulin, death from
atherosclerosis increased 3 fold in patients with
diabetes
“Ibelievethechiefcauseofprematuredevelopmentofatherosclerosisindiabetes,saveforadvancedage,isanexcessoffat,anexcessoffatinthebody,anexcessoffatinthedietandanexcessoffatintheblood.Withanexcessoffat,diabetesbegins,andwithanexcessoffatdiabeticsdie.”
Ø EliottPJoslin,MD1927
First ADA Standards of Medical Care
DiabetesCare1989,365-368
4pages10references
Now126pages100’sofreferences
4/27/19
4
RF Atherosclerosis
• Obesity• Hypertension• Dyslipidemia• Smoking• FHprematurecoronarydisease• Chronickidneydisease
Diabetes-Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes Mellitus
RiskEnhancers• Longduration(≥10yearsfortype2diabetesmellitus(S.4.3-20)or≥20yearsfortype1diabetesmellitus)
• Albuminuria≥30mcgofalbumin/mgcreatinine• eGFR<60mL/min/1.73m2• Retinopathy• Neuropathy• ABI<0.9
Tonellietal(2012)Lancet
4/27/19
5
http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/
AHA/ACC Management of Hyperlipidemia in Diabetes Endorsed by the ADA
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625
3. Inveryhigh-riskASCVD,useaLDL-Cthresholdof70mg/dL(1.8mmol/L)toconsideradditionofnonstatinstostatintherapy.
•Veryhigh-riskincludesahistoryofmultiplemajorASCVDeventsor1majorASCVDeventandmultiplehigh-riskconditions.
•Inveryhigh-riskASCVDpatients,itisreasonabletoaddezetimibetomaximallytoleratedstatintherapywhentheLDL-Clevelremains≥70mg/dL(≥1.8mmol/L).
•InpatientsatveryhighriskwhoseLDL-Clevelremains≥70mg/dL(≥1.8mmol/L)onmaximallytoleratedstatinandezetimibetherapy,addingaPCSK9inhibitorisreasonable,althoughthelong-termsafety(>3years)isuncertainandcost-effectivenessislowatmid-2018listprices.
Top 10 Take Home Messages
4/27/19
6
3. Inveryhigh-riskASCVD,useaLDL-Cthresholdof70mg/dL(1.8mmol/L)toconsideradditionofnonstatinstostatintherapy.
•Veryhigh-riskincludesahistoryofmultiplemajorASCVDeventsor1majorASCVDeventandmultiplehigh-riskconditions.
•Inveryhigh-riskASCVDpatients,itisreasonabletoaddezetimibetomaximallytoleratedstatintherapywhentheLDL-Clevelremains≥70mg/dL(≥1.8mmol/L).
•InpatientsatveryhighriskwhoseLDL-Clevelremains≥70mg/dL(≥1.8mmol/L)onmaximallytoleratedstatinandezetimibetherapy,addingaPCSK9inhibitorisreasonable,althoughthelong-termsafety(>3years)isuncertainandcost-effectivenessislowatmid-2018listprices.
Top 10 Take Home Messages
List of Statins by Intensity of LDL Lowering
When Statins Are Not Enough: The Role of Ezetimibe
1. Cannon CP, et al. N Engl J Med. 2015;372:2387-2397; 2. Garber A, et al. Endocr Pract. 2016;22:84-113; 3. ADA. Diabetes Care. 2016;39(suppl 1):S1-S112; 4. US FDA. Drugs@FDA. http://www.accessdata.fda.gov/
Scripts/cder/DrugsatFDA.
Whatdoesitdo?1
• Cholesterolabsorptioninhibitor• GreaterLDL-Creductionthanwithmoderate-intensitystatinalone
Newrecommendations2,3
Considerezetimibewithmoderate-intensitystatinforpatients:• Whocannottoleratehigh-intensitystatintherapy
• WithrecentACSandLDL-C≥50mg/dLwhocannottoleratehigh-intensitystatintherapy
Newrecommendations:evidence
• IMPROVE-IT:ezetimibevsPBOaddedtomoderate-intensitystatin1
• Participants:aged≥50years;ACSinprevious10days;LDL-C≥50mg/dL1
• SignificantreductionsvsPBO1,2• LDL-C:to53vs70mg/dL• MACE:6%infullstudypopulation;14%inpatientswithdiabetes
Safetyconsiderations4
• Contraindications:liverdisease,highALT;usewithstrongCYP3A4inhibitors,gemfibrozil,cyclosporine,danazol
• Myopathymorecommonathigherdoses
• Nodifferenceinmyopathy,prespecifiedsafetyendpointsvsPBOinIMPROVE-IT1
4/27/19
7
When Statins Are Not Enough: The Role of PCSK9 Inhibitors
1. US FDA. Drugs@FDA. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA; 2. ADA. Diabetes Care. 2016;39(suppl 1):S1-S112; 3. Garber A, et al. Endocr Pract. 2016;22:84-113; 4. Zimmerman MP. Am Health Drug Benefits. 2015;8:436-442; 5. Gidding SS, et al.
Circulation. 2015;132:2167-2192; 6. Zhang XL, et al. BMC Med. 2015;13:123; 7. Banach M, et al. Lipids Health Dis. 2015;14:167.
Whatdotheydo?1-3
• AntibodyinhibitorsofproteinthatregulateLDLreceptorrecycling(PCSK9serineprotease)
• ReduceLDL-Cby≈50%whenusedwithmaximalstatintherapy
• Preliminarydatasuggest≈50%reductioninCVevents
Whenwouldyouusethem?1
• ASCVD:adjuncttomaximalstatintofurtherreduceLDL-C
• Familialhypercholesterolemia(FH)• WithmaximalstatininHeFH:alirocumab,evolocumab
• WithotherLDLtherapiesinHoFH:evolocumab
RecognizingHeFHorHoFH?4,5
• LCL-C>190mg/dLorrelativeswithprematureASCVD
• LDL-C>400mg/dLandbothparentswithHeFH
• Geneticscreeningusuallynotneeded• FHisassociatedwithahighriskofprematureCVDanddeath
Safetyconsiderations1,6,7
• SCinjectionevery2weeks(bothagents)oroncemonthly(evolocumab)
• Generallywelltolerated• Caution:hypersensitivityreactions• NeurocognitiveAEsrequirefurtherinvestigation
Treatment of Hypertension: ADA • Bloodpressureshouldbemeasuredateveryroutineclinicalvisit.IfBP≥140/90mmHg,itshouldbeconfirmedonaseparatedaytodiagnosehypertension1
• Allhypertensivepatientswithdiabetesshouldmonitortheirbloodpressureathome1
• Target<140/90inallpatients1• <130/80maybeappropriateforhighCVDrisk(>15%),historyofCVA,retinopathy,albuminuria1
• <130/80isendorsedbytheAHA/ACCandAACE2,3
American Diabetes Association Dia Care 2019;42:S103-S123, 2019. 2.GarberAJ,etal.EndocrPract.2018;24:91-120.3.AHA/ACCguidelines
American Diabetes Association Dia Care 2019;42:S103-S123
©2019 by American Diabetes Association
**Thiazide-like diuretic; long-acting agents shown to reduce cardiovascular events, such as chlorthalidone and indapamide, are preferred. **Dihydropyridine calcium channel blocker (CCB).
4/27/19
8
Effects of Diabetes on ASCVD
LowWangCC,HessCN,HiattWR,GoldfineAB.Circulation.2016;133(24):2459-502.
Akt,proteinkinaseB;ERK,extracellularsignal-regulatedkinase;GlcNAc,N-Acetylglucosamine;IL,interleukin;JNK,c-JunN-terminalkinase;MAPK,mitogen-activatedproteinkinase;NF-κβ,nuclearfactor–kappabeta;NOS,nitricoxidesynthase;PI3K,phosphoinositide3-kinase;RNS,reactivenitrogenspecies;ROS,reactiveoxygenspecies.
Impact of Intensive Therapy in Diabetes in Major Clinical Trials
AdaptedfromBergenstalRM,etal.AmJMed2010;123:374e9-e18
Study A1c Microvascular CVD Mortality
DCCT/EDIC 9 → 9 & 7 ↓ ↓ ↔ ↓ ↔ ↔
UKPDS 9 → 7.9 & 7 ↓ ↓ ↔ ↓ ↔ ↓
ACCORD 8.3 → 7.5 & 6.4 ↓ ↔ ↑ ?
ADVANCE 7.5 → 7.0 & 6.4 ↓ ↔ ↔
VADT 9.4 → 8.5 & 6.9 ↓ ↔ ↔
Baseline StudyEndStdIntensive
LongTermFollow-upInitialTrial
↓ ↓
23
Legacy Effects: New T2DM UKPDS F/U NEJM 2008;359:1-13
MyocardialInfarctionHR0.85(0.74-0.97)
TotalMortalityHR0.87(0.79-0.96)
YearsSinceRandomization YearsSinceRandomization
4/27/19
9
Intensive Glycemic Control and Cardiac Outcomes DCCT/EDIC (1441 patients with T1DM)
• ~42%reductioninriskofafirstCVeventwithintensivetherapy
• Long-termbenefit
• 20%reductioninCVriskwitha10%reductioninA1C
NathanDM,ClearyPA,BacklundJY,etal..NEnglJMed2005;353:2643-53.
A1CLevels
Baseline EndofStudyTreatment EndofFollowUp
Conventional
Intensive
9.1±1.6%
9.1±1.6%
9.1±1.5%
7.4±1.1%
7.9±1.3%
7.8±1.3%
42% risk reduction
DCCT
Treatment
Mean 6.5 years
EDIC
Follow-up
Mean 17 years
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
0.12
0.10
0.08
0.06
0.04
0.05
0.00
Years since Entry
No. at Risk
Intensive
Treatment 705 683 629 113
Conventional
Treatment 714 688 618 92
Intensive
Treatment
Conventional
Treatment
Cum
ula
tive Incid
ence o
f A
ny P
redefined
CV
Outc
om
e
26
Concern for adverse CV events led the FDA to require demonstration of CV safety for new glucose-lowering drugs
• 1.Nissen.AnnInternMed2012;157:671–2.2.Nissenetal.JAMA2005;294:2581–6.3.Nissenetal.NEnglJMed2007;356:2457–71.4.ACCORDStudyGroup.NEnglJMed2008;358:2545–59.5.http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/%20guidances/ucm071627.pdf6.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf7.http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm376683.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
UGDP trial: tolbutamide discontinued due to increased CV mortality vs other treatment groups1
• Sponsorwithdrewapplication1
• WithdrawnintheEU1• UserestrictedinUS1**In2013,FDApanelvotedtoreducesafetyrestrictionsonrosiglitazone7
1961
2005
2007
2008
20082012
Muraglitazar found to potentially increase CV risk during FDA assessment2
Rosiglitazone associated with increased risk for MI and CV-related death3
ACCORD trial: intensive glucose lowering was associated with increased all-cause mortality4 HR1.22(95%CI1.01‒1.46);p=0.04
New FDA requirements5 New EMA requirements6 New diabetes drugs should demonstrate CV safety with meta-analysis and a CV outcome trial (CVOT)
UGDP: Tolbutamide vs insulin vs placebo
UGDP,Diabetes,1970
4/27/19
10
William T. Cefalu et al. Dia Care 2018;41:14-31 ©2018 by American Diabetes Association
Completed and Ongoing CVOTs
• CVOT are designed and powered to assess non-inferiority versus placebo in addition to standard of care in a high risk CVD patient population (prior CVD ± high risk patients without proven CVD). • Major endpoint composite of Major Adverse Cardiovascular Events: - Usual is 3 point MACE – new nonfatal MI, new stroke, CV death based on careful adjudication to confirm accuracy of the events*
• Key understandings: - Powered for safety. - Studied populations provide data on SECONDARY PROTECTION. - Original studies not powered for subgroup analysis - Different design does not consistently enable direct comparison of results of one study to another.
Cardiovascular Outcome Trials (CVOT)
Usualcare–glucoselowering,BPlowering,lipidloweringetc.
30
Contemporary Cardiovascular Outcome Trial Design for Type 2 Diabetes
• AdaptedfromGeigeretal.TherInnovationRegScience2014;1–15.
• 1.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
AimDetermineeffectofDrugXcomparedwithplacebo/comparatoronCVoutcomes,ontopofglucose-loweringandCVtherapiesadjustedaccordingtolocalguidelines,inpatientswithT2D
PlaceboHighCVriskpatients
Compositeprimaryendpoint
Statistics RRun-in
Events
DrugX
FDAmandatesthatCVsafetybedemonstratedinhighCVriskpopulation1Run-inhelpstoestablishpatientadherencetolong-termtreatmentandFUAllpatientsareonausualcarebackground(tocontroldiabetesandCVriskfactors);investigatorsencouragedtoadjusttherapyfollowinglocalguidelinesAsadjustmentofbackgroundtherapyisencouraged,CVOTsnotdesignedtoassessimpactofadifferenceinHbA1cbetweenstudyarmsFDArecommends3P-MACEasprimaryCVendpointorexpanded4P-MACE(e.g.,includinghospitalisationforunstableanginapectoris)1
4/27/19
11
Considerations for Interpretation of Contemporary CVOTs
Designfeatures
1.Hirshberg&Katz.DiabetesCare2013;36(suppl2):S253–8.
2.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
• MostCVOTsemployhierarchicaltestingtotestforsuperiorityfollowingestablishmentofnon-inferiority
• CVOTsaretypicallyevent-driven;studydurationcanonlybeestimated1
Powerandduration
• Primaryandsecondaryoutcomesvaryacrosstrials(3P-MACEand4P-MACEarecommonprimaryoutcomes)2Outcomes
• Inclusioncharacteristicsvaryacrosstrials(e.g.,degreeofpre-existingCVriskorpriorCVD,durationofT2D)
• Thisnecessitatescautionincomparingresultsacrosstrials1Population
Backgroundtherapy
• Trialsperformedonausualcarebackground(e.g.,highantihypertensiveandstatinuse)soCVriskfactors(e.g.BP,LDL-C)aregenerallywellcontrolled
• Investigatorsshouldadjustbackgroundtherapyaccordingtolocalguidelines1
DemonstrationofCVsafetyisrequiredbyregulatorsforneweranti-hyperglycemicdrugsas‘classeffects’cannotbeassumedbasedondrug-specifictrials
Study SAVOR EXAMINE TECOS CAROLINA CARMELINA
DPP4-i saxagliptin alogliptin sitagliptin linagliptin linagliptin
Comparator placebo placebo placebo sulfonylurea placebo
N 16,500 5,400 14,000 6,000 8,300
Results 2013 2013 2015 2017 2017
Study LEADER ELIXA SUSTAIN6 EXSCEL REWIND
GLP1-RA liraglutide lixisenatide semaglutide exenatideLR dulaglutide
Comparator placebo placebo placebo placebo placebo
N 16,500 14,000 6,000 5,400 9901
Results 2016 2015 2016 2018 2019
Study EMPA-REG CANVAS/-R DECLARE VERTIS-CV
SGLT-2-i empaglifozin canagliflozin dapagliflozin ertugliflozin
Comparator placebo placebo placebo placebo
N 7034 10,142 17,160 8238
Results 2015 2017 2019 2020
Large CV Outcomes Trials in Diabetes (Non-Insulin)
+ + +
+ + +
NEUTRAL
NEUTRAL
NEUTRAL
NEUTRAL
NEUTRAL NEUTRAL
NEUTRAL
Summary of CVD Trials – GLP-1 RA
MACE MI CVA CVdeath HHF AllDeathLiraglutide 0.87 0.88 0.89 0.78 0.87 0.85Semaglutide 0.74 0.74 0.61 0.98 1.11 NGExenatideQW 0.91 0.97 0.85 0.88 0.94 0.86Albiglutide 0.78 0.75 0.86 0.93 NG 0.93
HighlevelresultsofREWINDshowedsuperiorityin3-pointMACEoverplacebo.
1.MarsoSP,etal.NEnglJMed.2016;375:311-3222.MarsoSP,etal.NEnglJMed.2016;375:1834-18443.HolmanRRetalNEnglJMed2017;377(13):1228–12394.HernandezAFetalLancet.2018392(10157):1519–1529..